Investigational Drug Information for Rimiducid
✉ Email this page to a colleague
What is the drug development status for Rimiducid?
Rimiducid is an investigational drug.
There have been 21 clinical trials for Rimiducid.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).
There are seven US patents protecting this investigational drug and eighty-seven international patents.
Summary for Rimiducid
| US Patents | 7 |
| International Patents | 87 |
| US Patent Applications | 76 |
| WIPO Patent Applications | 81 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 1 (2018-12-27) |
| Vendors | 44 |
Recent Clinical Trials for Rimiducid
| Title | Sponsor | Phase |
|---|---|---|
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Poseida Therapeutics, Inc. | Phase 1 |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Poseida Therapeutics, Inc. | Phase 1 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Rimiducid
Top disease conditions for Rimiducid
Top clinical trial sponsors for Rimiducid
US Patents for Rimiducid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| rimiducid | ⤷ Try a Trial | Compositions and methods for treatment of cancer | Aleta Biotherapeutics Inc. (Natick, MA) | ⤷ Try a Trial |
| rimiducid | ⤷ Try a Trial | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Try a Trial |
| rimiducid | ⤷ Try a Trial | Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA) NOVARTIS AG (Basel, CH) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA) | ⤷ Try a Trial |
| rimiducid | ⤷ Try a Trial | Treatment of cancer using a CD33 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Try a Trial |
| rimiducid | ⤷ Try a Trial | Synthetic multimerizing agents | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rimiducid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| rimiducid | Australia | AU2016343809 | 2035-10-30 | ⤷ Try a Trial |
| rimiducid | Brazil | BR112018008326 | 2035-10-30 | ⤷ Try a Trial |
| rimiducid | Canada | CA3002674 | 2035-10-30 | ⤷ Try a Trial |
| rimiducid | Chile | CL2018001152 | 2035-10-30 | ⤷ Try a Trial |
| rimiducid | China | CN108602872 | 2035-10-30 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
